ALTO-101


Associated tags: Schizophrenia, Pharmacokinetics, Deficit spending, PDE4, CNS

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

Retrieved on: 
Tuesday, April 23, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Volunteering, CIAS, TDS, Safety, Pharmacokinetics, Neuroscience, Partnership, PDE4, Schizophrenia, Therapy, Patient, Multimedia, AUC, Absorption, Plasma, Deficit spending, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).
  • (Graphic: Alto Neuroscience, Inc.)
    “These positive results provide a strong indication that ALTO-101 could become an important therapeutic option for a broad range of indications,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.
  • “Oral PDE4 inhibitors have shown promise as pro-cognitive therapeutics but are associated with burdensome and dose-limiting side effects.
  • Despite these dosing and tolerability challenges, PDE4 inhibitors are used widely in other non-CNS indications, often with sub-optimal dosing regimens.